Finally, translating preclinical findings into well-controlled human studies is essential to determine whether AX can effectively improve muscle metabolism, insulin sensitivity, and lipid handling in individuals with obesity, metabolic syndrome, or type 2 diabetes. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.